Short answer
Claritev Corp (CTEV) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $257M (up 6.6% year over year) with net income of −$59M.
Q2 2026 key financials · XBRL
- Revenue
- $257M
- +6.6% YoY · +5.2% QoQ
- Net income
- −$59M
- +5.5% YoY · +19.5% QoQ
- Operating margin
- 9.1%
- EPS (diluted)
- −$3.48
- +8.7% YoY · +21.1% QoQ
Source: XBRL data from the Claritev Corp (CTEV) Q2 2026 10-Q on SEC EDGAR. USD.
Claritev Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Forward-looking statements subject to risks, uncertainties, and no obligation to update beyond legal requirements
Risk Factors
- DOJ antitrust risk changed: criminal grand jury proceeding closed July 6, 2026, while civil investigative demand remains ongoing
- Regulatory exposure: evolving healthcare laws could increase litigation involving Claritev’s cost-management products
- Litigation risk: provider and member lawsuits increasingly involve multiple parties, claims, and class-wide proceedings
- Operational risk: litigation may reduce client use of cost-management products and solutions
- Financial risk: insurance coverage may be insufficient for litigation-related losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Claritev Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.